Impaired Renal Function: Clinical Trials

5 trials for Impaired Renal Function, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 15Completed 5

Follow Impaired Renal Function: new trials by email Literature Review of Impaired Renal Function trials Research Report on Impaired Renal Function

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Aldafermin (NGM282) in Participants With Impaired Renal Function
Aldafermin (NGM282) - Impaired Renal Function
Phase 1CompletedNGM Biopharmaceuticals, Inc482019-11-082020-04-27
A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02
ELX-02 - Impaired Renal Function
Phase 1CompletedEloxx Pharmaceuticals, Inc.242019-01-042021-04-13
A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function
Roxadustat - Normal Renal Function, Impaired Renal Function
Phase 1CompletedAstellas Pharma Europe B.V.342016-12-122020-02-12
Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011
LEE011 - Normal Renal Function, Impaired Renal Function
Phase 1CompletedNovartis Pharmaceuticals382015-10-232020-12-19
Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function
SSP-004184 - Impaired Renal Function
Phase 1CompletedShire662012-10-292021-06-10

Narrower conditions

Renal Insufficiency (5)

Broader conditions

Female Urogenital Diseases (5)  ·  Female Urogenital Diseases and Pregnancy Complications (5)  ·  Kidney Diseases (5)  ·  Male Urogenital Diseases (5)  ·  Urogenital Diseases (5)  ·  Urologic Diseases (5)

Interventions

4,5-dihydro-2-(2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl)-4-methyl-4-thiazolecarboxylic acid (1)  ·  ELX-02 (1)  ·  aldafermin (1)  ·  ribociclib (1)  ·  roxadustat (1)

Sponsors

Astellas Pharma Europe B.V. (1)  ·  Eloxx Pharmaceuticals, Inc. (1)  ·  NGM Biopharmaceuticals, Inc (1)  ·  Novartis Pharmaceuticals (1)  ·  Shire (1)

Countries

United States (4)  ·  Germany (2)  ·  Bulgaria (1)  ·  Czechia (1)  ·  United Kingdom (1)

Results publications

PMID 33165773, PMID 36800111

NIH funding

2015 (1)